Royal Bank of Canada
RGLS

Royal Bank of Canada’s Regulus Therapeutics RGLS Stock Holding History

Royal Bank of Canada’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,366
Closed -$4K – 7296
2025
Q1 		$4K Sell
2,366
-5,386
-69% -$7.11K ﹤0.01% 6426
2024
Q4 		$12K Buy
7,752
+1,529
+25% +$2.35K ﹤0.01% 6301
2024
Q3 		$10K Buy
6,223
+275
+5% +$455 ﹤0.01% 6342
2024
Q2 		$11K Buy
5,948
+5,897
+11,563% +$13.7K ﹤0.01% 6308
2024
Q1 		$0 Sell
51
-29
-36% -$47 ﹤0.01% 7499
2023
Q4 		$0 Hold
80
– – ﹤0.01% 7504
2023
Q3 		$0 Sell
80
-126
-61% -$183 ﹤0.01% 7490
2023
Q2 		$0 Buy
206
+8
+4% +$11 ﹤0.01% 7594
2023
Q1 		$0 Sell
198
-178
-47% -$235 ﹤0.01% 7406
2022
Q4 		$0 Sell
376
-347
-48% -$546 ﹤0.01% 7632
2022
Q3 		$1K Buy
723
+90
+14% +$162 ﹤0.01% 7254
2022
Q2 		$1K Sell
633
-8
-1% -$19 ﹤0.01% 7189
2022
Q1 		$2K Sell
641
-65
-9% -$169 ﹤0.01% 7496
2021
Q4 		$2K Hold
706
– – ﹤0.01% 7420
2021
Q3 		$5K Hold
706
– – ﹤0.01% 7142
2021
Q2 		$6K Hold
706
– – ﹤0.01% 7034
2021
Q1 		$11K Hold
706
– – ﹤0.01% 6770
2020
Q4 		$9K Hold
706
– – ﹤0.01% 6439
2020
Q3 		$4K Sell
706
-13
-2% -$86 ﹤0.01% 6186
2020
Q2 		$5K Hold
719
– – ﹤0.01% 6047
2020
Q1 		$3K Sell
719
-4
-0.6% -$35 ﹤0.01% 6207
2019
Q4 		$6K Sell
723
-2
-0.3% -$14 ﹤0.01% 6307
2019
Q3 		$5K Sell
725
-66
-8% -$537 ﹤0.01% 6034
2019
Q2 		$10K Sell
791
-13
-2% -$150 ﹤0.01% 6030
2019
Q1 		$8K Sell
804
-41
-5% -$446 ﹤0.01% 6101
2018
Q4 		$8K Sell
845
-260
-24% -$4.3K ﹤0.01% 5995
2018
Q3 		$26K Sell
1,105
-147
-12% -$4.84K ﹤0.01% 5551
2018
Q2 		$99K Buy
1,252
+30
+2% +$2.48K ﹤0.01% 4811
2018
Q1 		$106K Buy
1,222
+309
+34% +$41.3K ﹤0.01% 4673
2017
Q4 		$114K Sell
913
-308
-25% -$39K ﹤0.01% 4742
2017
Q3 		$183K Sell
1,221
-313
-20% -$39.4K ﹤0.01% 4582
2017
Q2 		$182K Buy
1,534
+166
+12% +$27.7K ﹤0.01% 4416
2017
Q1 		$270K Sell
1,368
-16
-1% -$3.04K ﹤0.01% 4140
2016
Q4 		$374K Sell
1,384
-291
-17% -$94.6K ﹤0.01% 4002
2016
Q3 		$663K Sell
1,675
-181
-10% -$74.5K ﹤0.01% 3480
2016
Q2 		$644K Buy
1,856
+6
+0.3% +$4.3K ﹤0.01% 3474
2016
Q1 		$1.54M Buy
1,850
+102
+6% +$81.1K ﹤0.01% 2681
2015
Q4 		$1.83M Buy
1,748
+120
+7% +$120K ﹤0.01% 2616
2015
Q3 		$1.28M Sell
1,628
-87
-5% -$89.3K ﹤0.01% 2645
2015
Q2 		$2.25M Buy
1,715
+100
+6% +$161K ﹤0.01% 2226
2015
Q1 		$3.28M Buy
1,615
+413
+34% +$898K ﹤0.01% 1893
2014
Q4 		$2.31M Buy
1,202
+375
+45% +$667K ﹤0.01% 2214
2014
Q3 		$678K Buy
827
+128
+18% +$108K ﹤0.01% 3168
2014
Q2 		$675K Buy
699
+305
+77% +$261K ﹤0.01% 3164
2014
Q1 		$427K Buy
394
+294
+294% +$326K ﹤0.01% 3475
2013
Q4 		$89K Hold
100
– – ﹤0.01% 4644
2013
Q3 		$113K Buy
100
+50
+100% +$59K ﹤0.01% 4406
2013
Q2 		$59K Buy
+50
New +$47.5K ﹤0.01% 4580

Other funds holding RGLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Royal Bank of Canada's RGLS Position: Q2 2025 in Review

Royal Bank of Canada sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 2,366 shares — an estimated $4K sold.

Royal Bank of Canada first reported a position in RGLS in Q2 2013 and held it in 48 quarters. The position peaked at $3.28M in Q1 2015. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.

  • Royal Bank of Canada reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 2,366 Regulus Therapeutics shares in Q2 2025, an estimated $4K.
  • Royal Bank of Canada first reported a position in Regulus Therapeutics in Q2 2013 and held it in 48 quarters.
  • Royal Bank of Canada's Regulus Therapeutics position peaked at $3.28M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.

Based on Royal Bank of Canada's 13F filing for Q2 2025, filed 14 Aug 2025.